News
Interplay of TP53, ESR2 may expand treatment options for some TNBCs
Study finds interaction of TP53 mutational status and ESR2 expression influences survival in triple-negative breast cancer and suggests tamoxifen...
News
Systematic review: Patient navigation programs improve outcomes, have financial benefits
But 65% of studies used weak methodologies.
News
Enzalutamide boosts ADT benefit in metastatic hormone-sensitive prostate cancer
SAN FRANCISCO – In findings that may ultimately change clinical practice, the phase 3 ARCHES trial has shown that adding the androgen receptor...
News
Tivozanib has PFS benefit over sorafenib in hard-to-treat RCC
SAN FRANCISCO – In the TIVO-3 trial, tivozanib prolonged progression-free survival by about 2 months, compared with sorafenib, in patients with...
News
First-line avelumab/axitinib for RCC benefits wide range of patients
SAN FRANCISCO – Subgroup analyses of the JAVELIN Renal 101 trial show that first-line avelumab/axitinib yields better PFS and ORRs than sunitinib...
News
ARAMIS: Darolutamide shines in nonmetastatic CRPC
SAN FRANCISCO – The phase 3 ARAMIS trial is positive, showing that darolutamide more than halved the risk of metastases or death in men with...
News
Survival of patients with mCRPC on hormone therapy differs by race
SAN FRANCISCO – An analysis of male veterans finds that African American men with chemotherapy-naive mCRPC treated with abiraterone or...
News
Pembrolizumab-axitinib nearly halves risk of death in RCC
SAN FRANCISCO – Pembrolizumab and axitinib combination therapy netted superior progression-free and overall survival relative to sunitinib in...
News
Radioligand is highly active in metastatic castrate-resistant prostate cancer
SAN FRANCISCO – Lutetium-177 PSMA-617 (LuPSMA) netted a high rate of PSA response and impressive overall survival among patients who had run out...
News
Pancreatic cancer expression signature is linked to chemoresistance
SAN FRANCISCO – Whole-genome and RNA sequencing of pancreatic cancers in the COMPASS trial has tied an RNA expression signature to poorer survival...
News
Gastrectomy does not alter benefit of new oral chemo in gastric cancer
SAN FRANCISCO – In the phase 3 TAGS trial, the gastrectomy subgroup did have higher rates of grade 3 or 4 adverse events.
News
Cancer vaccine fails in CRC but trial yields lessons
SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...
News
Dual BRAF, MEK inhibition proves highly active in biliary tract cancer
SAN FRANCISCO – Patients with BRAF V600E–mutated biliary tract cancer in a basket trial had a response rate of 42% when given the combination of...
News
mRECIST response to kinase inhibitors predicts survival in HCC
SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...